PUVA therapy is known to be effective for treating cutaneous T-cell lymphoma (CTCL). Considering that adult T-cell leukemia/lymphoma (ATL) represents a T-lymphocytic proliferative disorder similar to CTCL, it is likely that PUVA therapy is effective for treating ATL. We applied PUVA therapy to a 53 year old man with acute (i.e. crisis)-type ATL associated with generalized erythematous papules, and succeeded in achieving a complete remission (CR). To elucidate the mechanism of PUVA therapy in this case, we compared ultrastructures of leukemic cells obtained before and after PUVA therapy by electron microscopy, and found that PUVA therapy caused apoptosis in leukemic cells in the peripheral blood. In this paper, the antitumor mechanism of PUVA is discussed, and its efficacy is emphasized.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ultra-high-frequency Ultrasound in the Objective Assessment of Chlormethine Gel Efficacy: A Case Report.
Acta Dermatovenerol Croat
November 2024
Agata Janowska, MD, Department of Dermatology, , University of Pisa, Via Roma 67, 56126, Pisa, Italy; Phone: +39 050 992436, Fax: +39 050 992556,
Mycosis fungoides (MF) represent the most frequent form of cutaneous T-cell lymphoma (CTCL). Chlormethine gel has been approved as first-line therapy in MF. The classification of early forms of MF is clinically and histologically complex even for experienced clinicians.
View Article and Find Full Text PDFWidespread Cutaneous Indeterminate Dendritic Cell Tumor (IDCT) With ETV3::NOAC2 Rearrangement Successfully Treated With PUVA Therapy: A Case Report.
Case Rep Hematol
November 2024
Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
The unique histiocytic entity of indeterminate dendritic cell tumor (IDCT) is known to cause diagnostic conundrum and treatment dilemmas with no published consensus on either. We report a rare case of cutaneous IDCT with ETV3::NOAC2 rearrangement providing further evidence to its association with this condition. With its ease of administration and minimal side effects, PUVA therapy can be successfully used to treat cutaneous forms of IDCT.
View Article and Find Full Text PDFGVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis.
Front Immunol
December 2024
Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Introduction: CAR T-cell therapy is highly effective, but also associated with unique toxicities. Because of the origin of T cells in patients who previously underwent allogeneic hematopoietic cell transplantation (alloHCT), graft-versus-host disease (GVHD) in the post-CAR T-cell setting poses a relevant concern but is only scarcely studied. Potential risk factors and mitigation strategies (from CAR T-cell modifications to clinical management) are yet to be determined.
View Article and Find Full Text PDFTreatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.
Leuk Res
December 2024
Bone Marrow Transplantation Unit, Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. Electronic address:
Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30-40 % of high-risk patients do not respond to monotherapy and/or experience side effects.
View Article and Find Full Text PDFUnlocking the promise of mesenchymal stem cells and extracorporeal photopheresis to address rejection and graft failure in intestinal transplant recipients.
Hum Immunol
November 2024
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA. Electronic address:
Introduction: In patients with irreversible intestinal failure, intestinal transplant has become a standard treatment option. Graft failure secondary to acute or chronic cellular rejection continues to be a significant challenge following transplant. Even with optimal immune suppression, some patients continue to struggle with refractory rejection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!